Initial Real-World Experience With PCSK-9 Inhibitors in Current Indications for Reimbursement in Spain
Rev Esp Cardiol (Engl Ed). 2019 Nov;72(11):968-970.
doi: 10.1016/j.rec.2019.03.008.
Epub 2019 May 16.
[Article in
English,
Spanish]
Affiliations
- 1 Departamento de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain. Electronic address: acorderofort@gmail.com.
- 2 Departamento de Cardiología, Hospital General Universitario de Valencia, Valencia, Spain.
- 3 Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain; Departamento de Cardiología, Complejo Hospital Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
- 4 Departamento de Cardiología, Hospital General Universitario de Elche, Elche, Alicante, Spain.
- 5 Departamento de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain.
No abstract available
Publication types
-
Multicenter Study
-
Observational Study
MeSH terms
-
Adult
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Anticholesteremic Agents / therapeutic use
-
Cholesterol, LDL / blood*
-
Cholesterol, LDL / drug effects
-
Female
-
Humans
-
Hyperlipidemia, Familial Combined / blood
-
Hyperlipidemia, Familial Combined / drug therapy*
-
Male
-
Middle Aged
-
Proprotein Convertase 1 / antagonists & inhibitors*
-
Proprotein Convertase 1 / blood
-
Retrospective Studies
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Anticholesteremic Agents
-
Cholesterol, LDL
-
PCSK1 protein, human
-
Proprotein Convertase 1
-
evolocumab
-
alirocumab